NCT02262806View on ClinicalTrials.gov

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 14, 2014

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
DiabetesLipodystrophyHyperlipidemia
Interventions
DRUG

Metreleptin

A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH